Fig. 7: Treatment with harmol delayed aging and reduced frailty in old mice.
(a–f) Longitudinal assessment of healthspan in 2 year-old male and female C57BL/6JHsdOla mice before (Pre) and after (Post) 2 months of treatment with 100 mg/kg harmol in the drinking water: (a) fasting (5 h) glucose levels (n = 5–7); (b) total blood cholesterol levels at the end of the intervention (n = 6–7); (c) rotarod test (n = 6–7); (d) maximal grip strength in grams relativized by animal body weight (BW) (n = 5–7); (e) maximal carrying load in the ladder climbing test represented as a percentage of the animal BW (n = 6–7); (f) hanging endurance in the grid hanging test (n = 6–7); (g) endurance capacity in a running treadmill test (n = 5–7); (h) maximal oxygen consumption at the end of the intervention (n = 6–7); (i) lactate increment in the VO2max test (n = 6–7). (j) Western blot against total myosin heavy chain (MHC) in protein extracts from soleus muscle of aged male mice treated with the indicated treatments and normalized to actin. (k) Percentage of frail mice (from a total of n = 5–7 at the end of the intervention. Horizontal lines in the dot-plots represent the average of the indicated number of individuals. Dots represent samples or measures from independent animals. Error bars represent the standard error of the mean. Statistical significance was assessed using the two-way ANOVA test with Sidak’s correction for multiple comparisons (a, c–g); the unpaired two-tailed Student t-test (b, h–j); or the Chi square test (k). P values are indicated when P < 0.05. Source data are provided as a Source Data file.
